NO20005588L - Inhibisjon av Helicobacter Pylori proliferasjon - Google Patents

Inhibisjon av Helicobacter Pylori proliferasjon

Info

Publication number
NO20005588L
NO20005588L NO20005588A NO20005588A NO20005588L NO 20005588 L NO20005588 L NO 20005588L NO 20005588 A NO20005588 A NO 20005588A NO 20005588 A NO20005588 A NO 20005588A NO 20005588 L NO20005588 L NO 20005588L
Authority
NO
Norway
Prior art keywords
somatostatin
inhibition
proliferation
helicobacter pylori
pylori
Prior art date
Application number
NO20005588A
Other languages
English (en)
Other versions
NO20005588D0 (no
Inventor
Hiroshi Kaneko
Terunori Mitsuma
Koichi Yamashita
Barry A Morgan
Original Assignee
Sod Conseils Rech Applic
Hiroshi Kaneko
Terunori Mitsuma
Koichi Yamashita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic, Hiroshi Kaneko, Terunori Mitsuma, Koichi Yamashita filed Critical Sod Conseils Rech Applic
Publication of NO20005588D0 publication Critical patent/NO20005588D0/no
Publication of NO20005588L publication Critical patent/NO20005588L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det er beskrevet en fremgangsmåte for anvendelse av somatostatin eller en somatostatin agonist for å inhibere proliferasjon av Helicobacter pylori (H. pylori), som omfatter administrering til en pasient som trenger det en effektiv mengde av nevnte somastotatin eller somatostatin agonist. Det er foretrukket at en somatostatin sub-type resepter 2 (SSTR-2) selektiv somatostatin agonist blir administrert i en fremgangsmåte som beskrevet heri. Inhibisjon av H. pylori proliferasjon er nyttig ved behandling av forskjellige gastroduodenal sykdommer så som peptisk sår, mage cancer og gastrisk lymfom.
NO20005588A 1998-05-07 2000-11-06 Inhibisjon av Helicobacter Pylori proliferasjon NO20005588L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/074,117 US5968903A (en) 1998-05-07 1998-05-07 Inhibition of H. pylori proliferation
PCT/US1999/010058 WO1999056769A2 (en) 1998-05-07 1999-05-06 Inhibition of helicobacter pylori proliferation

Publications (2)

Publication Number Publication Date
NO20005588D0 NO20005588D0 (no) 2000-11-06
NO20005588L true NO20005588L (no) 2001-01-05

Family

ID=22117835

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005588A NO20005588L (no) 1998-05-07 2000-11-06 Inhibisjon av Helicobacter Pylori proliferasjon

Country Status (6)

Country Link
US (1) US5968903A (no)
EP (1) EP1075273A2 (no)
JP (1) JP2002513769A (no)
AU (1) AU3975499A (no)
NO (1) NO20005588L (no)
WO (1) WO1999056769A2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ526676A (en) * 2001-01-12 2005-03-24 Sod Conseils Rech Applic Pharmaceutical compositions comprising somatostatin type-1 receptor agonists which inhibit vascular proliferation and method of use thereof
EP1813625B1 (en) * 2001-03-06 2009-04-29 Il Consorzio Ferrara Richerche Method of modulating the profileration of medullary thyroid carcinoma cells
WO2003046207A2 (en) * 2001-11-27 2003-06-05 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
US7122622B2 (en) * 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
CN1905895A (zh) * 2003-11-25 2007-01-31 诺瓦提斯公司 促生长素抑制素类似物治疗功效的生物标志
CA2726092A1 (en) 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
EP2719392B1 (en) 2008-06-12 2019-07-24 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
ES2351569B8 (es) * 2009-05-07 2012-06-20 Bcn Peptides S.A. Ligandos peptídicos de receptores de somatostatina.
EP2399931A1 (fr) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Nouveaux composés octapeptidiques et leur utilisation thérapeutique

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291022A (en) * 1975-03-11 1981-09-22 Sandoz Ltd. Organic compounds
US4133782A (en) * 1976-06-07 1979-01-09 The Salk Institute For Biological Studies Somatostatin analogs with dissociated biological activities
US4190575A (en) * 1977-12-27 1980-02-26 American Home Products Corporation Polypeptides related to somatostatin
IT1105131B (it) * 1977-06-08 1985-10-28 Merck & Co Inc Peptidi analoghi della somatostatina dotati di piu' lunga e maggiore attivita' biologica e relativo procedimento di protezione
DK153293C (da) * 1977-07-22 1988-11-14 Stamicarbon Katalysator til dehydrogenering af organiske forbindelser, isaer aminer, thioler og alkoholer, og fremgangsmaade til fremstilling deraf
US4211693A (en) * 1977-09-20 1980-07-08 The Salk Institute For Biological Studies Peptides with para-substituted phenylalanine
LU78191A1 (de) * 1977-09-28 1979-05-25 Ciba Geigy Ag Verfahren zur herstellung von neuen cyclopeptiden
CA1107273A (en) * 1978-05-19 1981-08-18 Chester A. Meyers Somatostatin analogs having a substituted tryptophyl residue in position eight
JPS5819669B2 (ja) * 1978-10-28 1983-04-19 白井松新薬株式会社 新規生理活性ペプチド化合物及びその製造法
US4215039A (en) * 1979-02-15 1980-07-29 American Home Products Corporation Somatostatin analogues
US4190648A (en) * 1979-03-13 1980-02-26 Merck & Co., Inc. Peptides having somatostatin activity
US4316890A (en) * 1979-03-16 1982-02-23 Ciba-Geigy Corporation Peptides and processes for the manufacture thereof
US4209426A (en) * 1979-05-29 1980-06-24 American Home Products Corporation Polypeptides related to somatostatin
US4328214A (en) * 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
US4235886A (en) * 1979-10-31 1980-11-25 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4310518A (en) * 1979-10-31 1982-01-12 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
DE3062075D1 (en) * 1979-11-27 1983-03-24 Sandoz Ag Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use
US4369179A (en) * 1979-12-14 1983-01-18 Ciba-Geigy Corporation Acylpeptides
EP0031303A3 (de) * 1979-12-21 1981-11-04 Ciba-Geigy Ag Cyclooctapeptide und pharmazeutische Präparate davon, sowie Verfahren zur Herstellung derselben und ihre Anwendung
US4282143A (en) * 1980-06-13 1981-08-04 American Home Products Corporation Octapeptides lowering growth hormone
DK81082A (da) * 1981-03-06 1982-09-07 Sandoz Ag Fremgangsmaade til fremstilling af polypeptider
US4360516A (en) * 1981-04-13 1982-11-23 Merck & Co., Inc. Modified D-retro cyclic hexapeptide somatostatin analogs
DE3264693D1 (en) * 1981-12-24 1985-08-14 Ciba Geigy Ag Cyclic octapeptides and pharmaceutical compositions thereof, and processes for their production and use
FR2522655B1 (fr) * 1982-03-05 1987-03-06 Sanofi Sa Analogues de la somatostatine possedant une liaison du type hydrazide et medicaments en contenant
US4486415A (en) * 1983-08-15 1984-12-04 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4485101A (en) * 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
US4522813A (en) * 1983-10-27 1985-06-11 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4684620A (en) * 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
HUT42101A (en) * 1985-01-07 1987-06-29 Sandoz Ag Process for preparing stomatostatine derivatives and pharmaceutical compositions containing such compounds
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US4650787A (en) * 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
US4585755A (en) * 1985-04-29 1986-04-29 Merck & Co., Inc. Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents
US4904642A (en) * 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
HU906340D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
US4871717A (en) * 1987-01-07 1989-10-03 Administrators Of The Tulane Educational Fund Peptides
EP0329295A1 (en) * 1988-02-01 1989-08-23 The Upjohn Company Renin inhibiting peptides with polar end groups
DK375789A (da) * 1988-08-18 1990-02-19 Syntex Inc Peptidderivater
CA2012115C (en) * 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
WO1990012811A1 (en) * 1989-04-26 1990-11-01 The Administrators Of The Tulane Educational Fund Linear somatostatin analogs
IT1240643B (it) * 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
HU207104B (en) * 1991-01-25 1993-03-01 Biosignal Kutato Fejlesztoe Kf Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
SI9420051A (en) * 1993-08-09 1996-12-31 Biomeasure Inc Chemical modified peptide derivatives, process for their preparation and their use in human therapy
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
WO1998008528A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
AU4133997A (en) * 1996-09-12 1998-04-02 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven

Also Published As

Publication number Publication date
EP1075273A2 (en) 2001-02-14
WO1999056769A3 (en) 2000-11-09
AU3975499A (en) 1999-11-23
US5968903A (en) 1999-10-19
WO1999056769A2 (en) 1999-11-11
JP2002513769A (ja) 2002-05-14
NO20005588D0 (no) 2000-11-06

Similar Documents

Publication Publication Date Title
WO2002015722A3 (en) Treatment of helicobacter with isothiocyanates
NO20005588L (no) Inhibisjon av Helicobacter Pylori proliferasjon
NO993979L (no) FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor
JP2004519423A5 (no)
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
PL366633A1 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
WO2001087306A8 (en) Compositions and methods for the treatment of colorectal cancer
NO940266L (no) Indre strålingsskade
DK0514452T3 (da) Anvendelse af insulin-sensibiliserende midler til behandling af hypertension
FI20011403A7 (fi) Menetelmä ja koostumukset vatsan sairauksien hoitoon
ATE193449T1 (de) Antiulcerogenes mittel und adhäsionsinhibitor für helicobacter pylori
WO2003024391A3 (en) Treatment and prevention of mucositis in cancer patients
NO980221L (no) Fremgangsmåte for behandling av tykktarmsadenomer
IS4907A (is) Nýjar bensímídasólafleiður sem vinna gegn magasári, aðferðir til að útbúa þær og lyfjablöndur sem innihalda þær
NO953281L (no) Anvendelse av oligosakkaridglykosider som hemmere av bakteriell adherens
NO20003813L (no) FremgangsmÕter for Õ redusere eller forhindre smerte ved bruk av spicamycin eller derivater derav
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
WO1999057278A3 (en) IMMUNIZATION AGAINST AND TREATMENT FOR INFECTION BY $i(H.PYLORI)
DK0821588T3 (da) Levobupivacain og anvendelse heraf som et anæstetikum til gravide kvinder
EP1073436A4 (en) IMPROVED METHOD FOR ERADICATION OF HELICOBACTER PYLORI
AU6701998A (en) Method for treatment of (h. pylori)
AU2412795A (en) Use of spiramycin for treating gastrointestinal disorders caused by (h. pylori)
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application